Thyrocare Technologies Ltd
Thyrocare Technologies Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth. Thyrocare expects continued strong growth, with revenue growth much above the industry’s mid-teen growth rate, aiming to maintain the current high growth trajectory.
From Thyrocare Technologies Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth.
- Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY.
- Vimta Labs acquisition is stabilizing; expected quarterly revenue from Vimta to be INR 3-4 crores for next 4 quarters before potential growth.
- Expansion in insurance-related partnerships is ongoing, contributing about 10-13% of partnership revenues with expectation to deepen further.
- Tanzania operations, still nascent, show potential with 100+ healthcare partners; revenue currently modest but expected to grow over time.
2 more points from Thyrocare Technologies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Radiology Business:
- No significant fresh capex planned; machines are old but still running.
- Refurbished options will be considered only when machines reach end of life.
- Overall Capex:
- Up to Q3 FY25, about INR 15 crores spent.
- Expected to spend another approximately INR 10 crores by year-end.
- Capex primarily directed towards new labs and network expansion.
- Strategic Investments:
- Acquisitions of Polo Labs and Vimta Clinical Diagnostics to increase presence in North and South India.
- Acquisition of Think Health to offer ECG at Home services, enhancing value to insurance partners.
2 more points from Thyrocare Technologies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Tech.'s management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q3 FY25 results?
Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth. Thyrocare expects continued strong growth, with revenue growth much above the industry’s mid-teen growth rate, aiming to maintain the current high growth trajectory.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
Radiology Business: - No significant fresh capex planned; machines are old but still running.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.